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 Sex Hormone-binding Globulin Selectively Modulates 
Estradiol-regulated Genes in MCF-7 Cells 
Besides acting as steroid carrier, new roles of 
SHBG on steroid action have emerged  [8,  9] ; in 
particular, the effects of SHBG initiated at the 
level of the cell membrane  [10,  11] , stimulate a 
specifi c intracellular pathway which leads to 
inhibition of breast cancer cell proliferation. We 
have demonstrated that SHBG rapidly stimulates 
cAMP in MCF-7 breast cancer cells  [12,  13] ; as a 
result of this intracellular pathway stimulation, 
the effects of estradiol on cancer cell prolifera-
tion are inhibited  [14] . Moreover, quite recently, 
SHBG was also reported to abolish the anti-apop-
totic effect of estradiol in MCF-7 cells  [15] . There-
fore, it appears that it is through these active and 
specifi c processes, that SHBG inhibits estradiol-
induced effects on cancer cell proliferation. This 
is the fi rst study that determines if these SHBG-
activated pathways initiate specifi c gene tran-
scription. 
 Materials and Methods 
 & 
 Cell Cultures 
 Estrogen-dependent MCF-7 breast cancer cells 
were routinely maintained in 25  cm 2 fl asks at 
37 ˚ C in 5  % CO 2 and 95  % humidity, in RPMI 1640 
 Introduction 
 & 
 Estradiol increases breast cancer cell prolifera-
tion and tumorigenesis  [1,  2] . In recent years, 
thanks to the advent of microarray technology, 
the profi ling of estrogen-regulated genes in 
breast cancer cells has become possible. Most 
studies had identifi ed genes overexpressed in 
breast cancer or patterns of gene expression 
related to disease outcome  [3,  4] and therapy 
responsiveness  [5] . Furthermore, the exact role 
of estrogen-regulated gene expression in estro-
gen-sensitive breast cancer cells has also been 
investigated. In breast cancer cells, estradiol 
upregulates, among others, genes positively 
affecting cell proliferation and cell cycle progres-
sion, while it downregulates transcriptional 
repressors, anti-proliferative and pro-apoptotic 
genes  [6] . The differential modulation of these 
genes, altogether, contributes to the estradiol 
induction of proliferation and inhibition of apop-
tosis in breast cancer. 
 The effects of estradiol on proliferation and apop-
tosis in breast cancer cells can be effi ciently 
inhibited by Sex Hormone-Binding Globulin 
(SHBG), a glycoprotein of human plasma that 
specifi cally binds androgens and estradiol  [7] . 
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 Abstract 
 & 
 Human sex hormone-binding globulin inhi-
bits the effects of estradiol on proliferation and 
apoptosis of breast cancer cells. We report here 
the effect of sex hormone-binding globulin on 
estradiol regulation of gene expression in MCF-7 
breast cancer cells using a selected set of genes. 
Estradiol upregulates genes that are positive 
regulators of proliferation (e.g., bcl-2, c-fos, c-
myc, cyclin D) or / and related to more aggres-
sive form of breast cancer (e.g. BRCA-1, EGF-R) 
and downregulates two genes (c-jun and ER  ). 
Sex hormone-binding globulin modulates only 
a selected group of estradiol-controlled genes 
(inhibiting upregulation of bcl-2, c-myc, EGF-R, 
PR, and downregulation of ER  ), starting 48 hours 
after treatment. Our study demonstrates that in 
breast cancer cells, sex hormone-binding globu-
lin is effective on few selected genes which are 
involved in cell growth and apoptosis or related 
to cell estrogen-dependence and that the pro-
tein regulation of estradiol effect is selected and 
specifi c. Sex hormone-binding globulin action in 
estrogen breast cancer cells is strongly associ-
ated to cell growth and estrogen-sensitivity. 
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(Sigma-Aldrich, St Louis, MO, USA) with the addition of 100  IU /
 ml penicillin and 100   g / ml streptomycin, and supplemented 
with 10  % heat inactivated FBS (Euroclone, Wetherby, West York, 
UK). Once a week, cells were detached with trypsin / EDTA and 
re-seeded at a dilution of 1:2 and 1:4. Twenty-four hours before 
experiments, cells were switched to RPMI 1640 without phenol 
red supplemented with 10  % FBS specifi cally treated to remove 
steroids and bovine SHBG. 
 Gene array 
 MCF-7 cells (1.5 × 10 6 ) were seeded in 75  cm 2 fl asks and treated 
as follows: a) cells under basal conditions; b) cells treated with 
10  nM estradiol (Sigma-Aldrich, St. Louis MO, USA) for different 
times (6, 24, 48, 72 hours); c) cells treated with 50  nM SHBG for 
40 minutes. Human SHBG (a gift from G.L. Hammond, B.C. 
Research Institute for Children ’ s and Women ’ s Health, Vancou-
ver B.C., Canada), was charcoal-treated before use to remove the 
dihydrotestosterone (DHT) used for storage; d) cells treated with 
50  nM SHBG for 40 minutes, thereafter, SHBG was washed off 
the cells before exposure to estradiol for the time indicated 
above. All of the treatments were repeated every day when 
experiment was prolonged over 24 hours. 
 Human GEArray kits for the study of estrogen-regulated genes 
(SuperArray, Bethesda, MD) were used to study the gene expres-
sion profi les of untreated and treated MCF-7 cells. Hybridization 
was performed according to manufacturer ’ s instructions. Briefl y, 
by using the TRIzol Reagent (Invitrogen, Groningen, The Nether-
lands) following the method developed by Chomczynski and 
Sacchi  [16] , total RNA was extracted from MCF-7 cells in differ-
ent conditions. RNA was used as a template for biotinylated 
probe synthesis. For probe synthesis, each RNA sample (7.5   g) 
was combined with a primer mix, and with 80  U AMV reverse 
transcriptase (Finnzymes, Finland), 50  U Rnase inhibitor (Amer-
sham, Little Chalfont, Buckinghamshire, UK), and a dNTP mix 
with biotin-16-dUTP (Roche Applied Science, Penzberg, Ger-
many) and was incubated for 120 minutes at 42 ˚ C. Filters were 
hybridized overnight at 68 ˚ C with denatured biotinylated cDNA 
probes; then they were extensively washed and incubated with 
alkaline phosphatase-conjugated streptavidin (1:5000). Gene 
expression was detected by chemiluminescence by using the 
alkaline phosphatase substrate CDP-Star. Spots were photo-
graphed with the Kodak EDAS 290 system (Eastman Kodak Com-
pany, Rochester, NY). Densitometric analysis was performed by 
using the Kodak 1D Image Analysis software. The negative con-
trol pUC18 DNA was used for background subtraction. The rela-
tive abundance of each transcript was estimated by comparing 
its signal intensity to the signal derived from positive controls, 
  -actin and GAPDH. Experiments were performed in triplicate. 
 RNA extraction and RT-PCR analysis 
 MCF-7 cells were seeded in 75  cm 2 fl asks and treated as above. 
Total RNA was extracted from cells using TRIzol Reagent (Invit-
rogen, Groningen, The Netherlands), as above. Total RNA was 
reverse-transcribed at 42 ˚ C for 40 minutes using AMV reverse 
transcriptase (Finnzymes, Finland) and oligodT primer (Invitro-
gen, Groningen, The Netherlands). The PCR reaction system con-
tained 5   l of 10X PCR buffer, 10   l of RT product, 0.2  mM dNTP 
(Finnzymes, Finland), 1.25  U Taq DNA polymerase (Finnzymes, 
Finland), 50  ng each of sense and anti-sense primers in a total 
volume of 50   l. Primers: 5  - CGA CTT CGC CGA GAT GTC CAG 
GCA G and 3  - ACT TGT GGC CCA GAT AGG CAC CCA G for bcl-2; 
5  - GGA AGA AAT TCG AGC TGC TG and 3  - GCT GTC GTT GAG 
AGG GTA GG for c-myc; 5  - AGA AGA AAC GGA GGG GAT GGA A 
and 3  - TTG GGG TGA TGG CTA AAG GAG A for EGF-R; 5  - CAT 
AAC GAC TAT ATG TGT CCA GCC and 3  - AAC CGA GAT GAT GTA 
GCC AGC AGC for ER  ; 5  -CTC ACC CTG AAG TAC CCC ATC G and 
3  -CTT GCT GAT CCA CAT CTG CTG G for   -actin. The expected 
PCR products were 389 for bcl-2, 458  bp for c-myc, 424 for EGF-
R, 659 for ER  , and 885 for   -actin. Amplifi cation was carried out 
as follows; for bcl-2: 1X (95 ˚ C, 3  min); 40X (95 ˚ C, 30  sec; 65 ˚ C, 
1  min; 72 ˚ C, 30  sec); and 1X (72 ˚ C, 7  min). For c-myc and EGF-R: 
1X (95 ˚ C, 3  min); 35X (95 ˚ C, 30  sec; 60 ˚ C, 30  sec; 72 ˚ C, 30  sec); and 
1X (72 ˚ C, 7  min). For ER  and   -actin: 1X (95 ˚ C, 3  min); 35X (95 ˚ C, 
30  sec; 65 ˚ C, 30  sec; 72 ˚ C, 30  sec); and 1X (72 ˚ C, 7  min). PCR prod-
ucts were electrophoresed on 1.5  % agarose gel in the presence of 
ethidium bromide. Gels were photographed and analyzed with 
the Kodak 1D Image Analysis software. The net intensity of 
bands in each experiment was normalized to the intensity of the 
corresponding   -actin band before comparison between treated 
cells and untreated control. 
 Western blot analysis 
 1 × 10 6 cells were seeded in 75  cm 2 fl asks and treated as above for 
3 days. After treatment, cells were lysed in RIPA buffer (PBS, 
pH  =  7.4, 1  % Nonidet P40, 0.1  % SDS, 0.5  % sodium deoxycholate, 
100   g / ml PMSF, 30   l aprotinin, 100  mM NaVO 4 ), extracted at 
4 ˚ C for 30 minutes, and centrifuged at 4 ˚ C for 20 minutes at 
15000 × g . Equal amounts of protein (50   g protein / lane) were 
subjected to SDS-PAGE (T  =  8  % ) and electroblotted onto a PVDF 
membrane; the membrane was probed with the following pri-
mary antibodies: anti-bcl-2 (  C-21, 1:400 dilution, Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA); anti c-myc (#06-340, 
1:500 dilution, Upstate, Lake Placid, NY, USA); anti-ER  (HC-20, 
1:500 dilution, Santa Cruz Biotechnology Inc, Santa Cruz, CA, 
USA); anti-actin (Monoclonal Anti-actin clone AC-40, 1:1000 
dilution, Sigma, Saint Louis, MI, USA), to check protein loading. 
 Proteins were detected with ECL Western blot reagents follow-
ing manufacturer ’ s instructions, and photographed with the 
Kodak EDAS 290 system (Eastman Kodak Company, Rochester, 
NY). Densitometric analysis was performed by using the Kodak 
1D Image Analysis software. 
 Statistical analysis 
 Data are expressed throughout as means  ±  SEM, calculated from 
at least three different experiments. Statistical comparisons 
between groups were performed with analysis of variance (one-
way ANOVA) and the threshold of signifi cance was calculated 
with the Bonferroni test. Statistical signifi cance was set at 
p  <  0.05. 
 Results 
 & 
 Estradiol and SHBG effect on gene expression in MCF-7 
cells 
 The GEArray technique allowed us to evaluate the expression in 
MCF-7 cells of 23 genes that are reported in  Table 1 . Among 
them, we could not observe any expression at any time of 6 
genes (EGF, ER  , H-ras, PRL, telomerase, TGF  ). The remaining 17 
genes were expressed in untreated cells at different abundance 
levels and estradiol regulated 13 of these genes. Estradiol in 
MCF-7 cells upregulated the expression of 11 genes (bcl-2, 
BRCA1, Cathepsin D, c-fos, c-myc, Cyclin D, EBAG9, EGF-R, Kera-
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tin 19, PR and pS2) while it downregulated the remaining two 
genes (c-jun and ER  ), following different temporal schedules. 
 SHBG alone had no detectable effect on basal gene expression in 
MCF-7 cells and its effect on estradiol gene regulation was 
detectable only after 48 – 72 hours of treatment. In these experi-
mental conditions, SHBG was effective in modifying estradiol 
effect on selected genes as showed in  Table 2 . We observed, in 
fact, in MCF-7 cells pre-treated with SHBG an inhibition of estra-
diol upregulation of bcl-2, c-myc, EGF-R and PR and of estradiol 
downregulation of ER  . 
 SHBG regulation of E 2 stimulated genes involved in cell 
proliferation and survival 
 Accordingly to previous reports, estradiol treatment of MCF-7 
cells upregulated bcl-2, a gene widely known for its anti-apop-
totic properties; and here we demonstrated that SHBG pretreat-
ment is able to inhibit the estradiol effect. As shown in     Fig. 1 , 
panel  A , the estradiol upregulation of bcl-2 mRNA was inhibited 
by SHBG pretreatment. In     Fig. 1 , panel  B , the effect of estradiol 
and SHBG / estradiol treatment on bcl-2 protein levels is also 
reported. Estradiol was signifi cantly effi cient in increasing bcl-2 
protein levels and pre-treatment with SHBG partially reduced 
its expression. 
    Fig. 2 , panel  A reports the behavior of c-myc expression. Estra-
diol upregulated c-myc mRNA expression while SHBG pre-treat-
ment inhibited it. Analysis of protein levels confi rmed RT-PCR 
data (    Fig. 2 , panel  B ). 
 SHBG regulation of E 2 stimulated genes encoding for 
growth factor receptors 
 Among genes encoding for growth factors and upregulated by 
estradiol, we show here that EGF-R mRNA expression was 
induced by steroid treatment (    Fig. 3 , panel  A ) and that SHBG 
pre-treatment inhibited this estradiol effect. Moreover, the data 
was confi rmed by analysis of protein levels (    Fig. 3 , panel  B ). 
 SHBG regulation of steroid receptor expression (ER  and 
PR) 
 Estradiol, as expected, downregulated mRNA expression of its 
receptor ER  (    Fig. 4 , panel  A ) and after pre-treatment with 
SHBG mRNA levels of ER returned to basal levels. The same effect 
was observed as protein levels are concerned (    Fig. 4 , panel  B ). 
 As progesterone receptor is concerned, we confi rmed our previ-
ously results  [17] indicating that estradiol induces PR expression 
and that pretreatment with SHBG determine a reduction of PR to 
basal levels, again at both mRNA and protein levels. 
 Discussion 
 & 
 In the present paper we demonstrate that SHBG affects estradiol 
gene regulation on selected genes, that are bcl-2, c-myc, EGF-R, 
ER  and PR. The effect observed here on bcl-2 expression may be 
one of the mechanisms elicited by SHBG to restore apoptosis in 
breast cancer cells under estrogen action. We recently reported 
 [15] that SHBG, after interacting with MCF-7 cell membranes, 
antagonizes the anti-apoptotic effect of estradiol; thus, the 
present observation on bcl-2 expression in MCF-7 cells confi rms 
the involvement of SHBG in abrogating the anti-apoptotic effect 
of estradiol. In fact, the proto-oncogene bcl-2 is widely known to 
inhibit apoptosis  [18,  19] and it is over-expressed in many tumors 
including breast cancer  [20] . Estradiol in MCF-7, ZR.75 and T47D 
breast cancer cells induces bcl-2 gene and cognate protein 
expression  [21,  22] , and our data are completely in line with 
 Table 1  Expression of estradiol-regulated genes in MCF-7 cells 
 Gene Name  Gene Bank No.  10  nM estradiol 
   6  h  24  h  48  h  72  h 
 bcl-2  M14745  1.94  1.82  2.47  3.44 
 BRCA1  U68041  0.93  0.95  3.66  1.77 
 Cathepsin D  M11233  0.96  1.55  1.86  1.65 
 c-fos  V01512  1.98  1.99  1.65  1.50 
 c-jun  AF022805  1.34  1.20  0.76  0.56 
 c-myc  J00120  2.45  3.00  2.90  2.31 
 COX7RP  AB007618  0.75  0.86  1.12  1.15 
 Cyclin D  M64349  0.82  0.86  1.66  1.52 
 EBAG9  AB007619  0.94  1.08  1.02  2.43 
 EFP  D21205  0.85  0.86  1.54  1.20 
 EGF  X04571  not detectable 
 EGF-R  X00588  1.18  1.24  1.65  2.83 
 ER   NM_000125  1.16  0.61  0.34  0.37 
 ER   AB006590  not detectable 
 HMG1  NM_002128  0.75  0.82  0.95  1.19 
 H-ras  NM_005343  not detectable 
 Keratin 19  NM_002276  0.79  1.28  2.26  1.82 
 PR  M15716  1.93  5.31  4.75  19.9 
 PRL  M29386  not detectable 
 pS2  NM_003225  1.15  1.32  2.42  2.00 
 Telomerase  AF015950  not detectable 
 TGF   NM_003236  not detectable 
 WISP2  NM_003881  0.86  0.81  1.40  1.18 
 Table 1 reports the 23 gene spotted on GEArray membrane, their accession codes, and their relative abundance after estradiol treatment for different time; relative abundance 
was calculated as the ratio between intensity values after / before treatments. Upregulated genes and their relative abundance values are reported in bold; downregulated genes 
are reported in italics. 
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these observations. In MCF-7 cells estradiol upregulates bcl-2 
transcription and two different EREs were identifi ed in bcl-2 
coding region  [23] ; moreover the upregulation of bcl-2 was 
strictly related to estradiol inhibition of apoptosis in this cell 
line. Stable overexpression of bcl-2 in MCF-7 cells resulted in 
suppression of apoptosis induced by several chemotherapy 
agents while pretreatment with the pure antiestrogen ICI 
182,780 enhanced induced apoptosis  [24] . 
 Another important target of estradiol in breast cancer is the 
proto-oncogene c-myc. It is well-known how estradiol induces a 
rapid and robust induction of c-myc in breast cancer cells  [25] . 
The c-myc, in turn, acts on multiple targets that are key cell cycle 
regulators; in particular, it increases the expression of cyclin E 
and CDK4  [26,  27] . As reported for bcl-2, our data show that 
estradiol induces c-myc expression that is maximal after 24 
hours, and that SHBG abrogates estradiol effect in MCF-7 cells 
treated for 72 hours. Since aromatase inhibitors and antiestro-
gens induce growth suppression and cell cycle arrest of breast 
cancer cells, together with apoptosis induction, and decrease 
of both bcl-2 and c-myc expression  [28] , our data suggest 
that SHBG behavior on c-myc as well as on bcl-2 is like to that of 
antiestrogens. We also report that SHBG inhibits the estradiol 
induction of EGF-R. EGF-R or HER1 is a member of the epidermal 
growth factor family of trans-membrane receptors  [29] and 
it has been reported to be induced by estradiol  [30] . Overexpres-
sion of EGF-R in breast cancer, that has been reported to occur 
in up to 14  % of tumors  [31] , is considered a negative prognostic 
factor  [32] , especially if it occurs together with over-expression 
of other genes such as c-myc  [33] . Moreover, EGF-R is involved 
in a bidirectional cross-talk with estrogen receptors and the 
activation of the EGF-R-derived signaling pathway could amplify 
estradiol effect in breast cancer  [34] . Therefore, SHBG, abolish-
ing the estradiol induction of EGF-R expression, is able to 
break the functional loop between the two pathways, reducing 
breast cancer cell proliferation and growth. Lastly, we show here 
that estradiol is able to downregulate the expression of its 
own receptor, ER  , effect that has been known for a long time. In 
fact, a single injection of estradiol determinates an 80  % reduc-
tion of binding capacity in cytosol extracts from rat uteri  [35] . 
On the other side, adaptation of MCF-7 cells to long term 
estrogen deprivation results in MCF-7 hypersensibility to 
estradiol and leads to an increase of ER  [36] . Here we show that 
SHBG is able to revert the downregulation of ER  induced by 
estradiol. This effect could also be linked to apoptosis induction 
and cell growth inhibition, since, as reported by other authors 
 [37,  38] , both phenomena were observed when ER  expression 
was increased in association with bcl-2 reduction. As PR modu-
lation is concerned, SHBG completely inhibits the strong 
upregulation induced by estradiol both at mRNA and protein 
levels as previously reported  [17] ; data reported in the present 
paper, obtained from gene array, further confi rm our previous 
observation. 
 The selectivity of SHBG effect on gene expression confi rms that 
SHBG regulation of estradiol effect in MCF-7 cells is not a general 
effect, due to the steroid sequester. As already suggested 
 [9,  15,  39,  40] , SHBG is likely to counteract estradiol action in a 
specifi c manner. Estradiol regulates the proliferation of breast 
cancer cells and this property is the key-stone of antihormone 
therapy with antiestrogens and aromatase inhibitors. Here we 
show that genes upregulated by estradiol are almost all positive 
regulators of proliferation (e.g., bcl-2, c-fos, c-myc, cyclin D) or /
 and related to more aggressive form of breast cancer (e.g., BRCA-
1, EGF-R). In addition, we observed that in our set, estradiol 
caused the downregulation of two genes (c-jun and ER  ). Our 
data, even though regarding few genes, are mainly in line with 
the report from Frasor et al.  [6] which observed that in general 
estradiol causes the upregulation of positive proliferation regu-
lator genes and the downregulation of negative proliferation 
regulators. 
 Estradiol followed a precise temporal schedule in our study as in 
previous reports  [6] in regulating gene expression. It is notewor-
thy that SHBG effect was detectable only after 48 – 72 hours and 
not at earlier time. It is thus conceivable that SHBG has a late 
effect on estradiol gene regulation. The absence of SHBG effect 
 Table 2  Effect of SHBG on the expression of estradiol-regulated genes in 
MCF-7 cells 
 Gene Name  Gene Bank No.  SHBG / estradiol 
   48  h  72  h 
 bcl-2  M14745  2.15 
 (2.47) 
 1.58  
 (3.44) 
 BRCA1  U68041  3.51 
 (3.66) 
 2.00 
 (1.77) 
 Cathepsin D  M11233  1.82 
 (1.86) 
 1.66 
 (1.65) 
 c-fos  V01512  1.62 
 (1.65) 
 1.52 
 (1.50) 
 c-jun  AF022805  0.68 
 (0.76) 
 0.53 
 (0.53) 
 c-myc  J00120  2.87 
 (2.90) 
 0.57  
 (2.31) 
 COX7RP  AB007618  1.05 
 (1.12) 
 1.32 
 (1.15) 
 Cyclin D  M64349  1.68 
 (1.66) 
 1.53 
 (1.52) 
 EBAG9  AB007619  1.06 
 (1.02) 
 2.70 
 (2.43) 
 EFP  D21205  1.47 
 (1.47) 
 1.38 
 (1.20) 
 EGF  X04571  N.D.  N.D. 
 EGF-R  X00588  1.69 
 (1.65) 
 0.56  
 (2.83) 
 ER   NM_000125  1.62  
 (0.34) 
 1.34  
 (0.37) 
 ER   AB006590  N.D.  N.D. 
 HMG1  NM_002128  1.19 
 (0.95) 
 1.56 
 (1.19) 
 H.ras  NM_005343  N.D.  N.D. 
 Keratin 19  NM_002276  1.96 
 (2.26) 
 1.91 
 (1.82) 
 PR  M15716  3.50  
 (4.75) 
 2.76  
 (19.9) 
 PRL  M29386  N.D.  N.D. 
 pS2  NM_003225  2.75 
 (2.42) 
 1.89 
 (2.00) 
 Telomerase  AF015950  N.D.  N.D. 
 TGF   NM_003236  N.D.  N.D. 
 WISP2  NM_003881  1.58 
 (1.40) 
 1.20 
 (1.18) 
 Table 2 reports the 23 gene spotted on GEArray membrane, their accession codes, 
and their relative abundance after SHBG / estradiol treatment for 48 or 72 hours; 
relative abundance was calculated as the ratio between intensity values after / before 
treatments. Relative abundance of gene expression after treatment with estradiol 
alone is reported in brackets; genes selectively regulated by SHBG are marked by 
arrows   and bolded 
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at early times supports the hypothesis, recently suggested  [15] , 
that SHBG does not interfere directly with the estradiol nuclear 
receptor pathway. In fact, we recently reported that in MCF-7 
cells SHBG  [15] is not able to inhibit estradiol-induced transcrip-
tion in an ERE-tk-luciferase system, while it can interfere with 
membrane-initiated estradiol pathway  [9] . 
0
1
2
3
4
5
6
  180 kDaEGF-R
42 kDaactin
A B
43214321
0
1
2 ***
# #
***
# # #
n
et
 i
n
te
n
si
ty
(f
o
ld
 c
h
a
n
g
e)
;
b
a
sa
l=
1
n
et
 i
n
te
n
si
ty
(f
o
ld
 c
h
a
n
g
e)
;
b
a
sa
l=
1
ba
sa
l
SH
B
G
E
2/
SH
B
GE
2
ba
sa
l
SH
B
G
E
2/
SH
B
GE
2
EGF-R
βactin
424 bp
885 bp
 Fig. 3  Effect of SHBG and estradiol on EGFR. A 
representative experiment of RT-PCR (panel  A ) and 
western blot (panel  B ) for EGFR mRNA and protein 
were performed in MCF-7 cells treated with SHBG 
and estradiol for 72 hours ( lane 1 : untreated control; 
 lane 2 : 10  nM estradiol;  lane 3 : 50  nM SHBG;  lane 
4 : 50  nM SHBG  +  10  nM estradiol). Histograms: 
semiquantitative analysis of RT-PCR and western 
blot results; net intensity was determined as the 
ratio between treated cells and untreated controls. 
Results are expressed as means  ±  SEM, n  =  3. 
Signifi cance  vs. basal:   * * *  p  <  0.001; signifi cance  vs. 
estradiol:  ## p  <  0.01,  ### p  <  0.001. 
bcl-2
885 bpβactin
26 kDa
42 kDa
bcl-2
actin
A B
1         2         3        4 1         2         3          4
0
1
2
ba
sa
l
SH
B
G
E
2/
SH
B
G
0.0
2.5
5.0
7.5
n
et
 i
n
te
n
si
ty
(f
o
ld
 c
h
a
n
g
e)
;
b
a
sa
l=
1
n
et
 i
n
te
n
si
ty
(f
o
ld
 c
h
a
n
g
e)
;
b
a
sa
l=
1
**
# #
***
# # #
389 bp
E
2
ba
sa
l
SH
B
G
E
2/
SH
B
GE
2
 Fig. 1  Effect of SHBG and estradiol on bcl-2. A 
representative experiment of RT-PCR (panel  A ) and 
western blot (panel  B ) for bcl-2 mRNA and protein 
performed in MCF-7 cells treated with SHBG and 
estradiol for 72 hours ( lane 1 : untreated control; 
 lane 2 : 10  nM estradiol;  lane 3 : 50  nM SHBG;  lane 
4 : 50  nM SHBG  +  10  nM estradiol). Histograms: 
semiquantitative analysis of RT-PCR and western 
blot results; net intensity was determined as 
the ratio between treated cells and untreated 
controls. Results are expressed as means  ±  SEM, 
n  =  3. Signifi cance  vs. basal:   * *  p  <  0.01,   * * *  p  <  0.001; 
signifi cance  vs. estradiol:  ## p   <  0.01,  ### p  <  0.001. 
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 Fig. 2  Effect of SHBG and estradiol on c-myc. 
A representative experiment of RT-PCR (panel  A ) 
and western blot (panel  B ) for c-myc mRNA and 
protein were performed in MCF-7 cells treated with 
SHBG and estradiol for 72 hours ( lane 1 : untreated 
control;  lane 2 : 10  nM estradiol;  lane 3 : 50  nM SHBG; 
 lane 4 : 50  nM SHBG  +  10  nM estradiol). Histograms: 
semiquantitative analysis of RT-PCR and western 
blot results; net intensity was determined as the 
ratio between treated cells and untreated controls. 
Results are expressed as means  ±  SEM, n  =  3. 
Signifi cance  vs. basal:   * * *  p  <  0.001; signifi cance  vs. 
estradiol:  ### p  <  0.001. 
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 Since SHBG effect in cells is initiated at membrane level  [13] , we 
suggest that the  “ link ” between estradiol and SHBG might reside 
somewhere between the outer side of membrane and nucleus. 
We recently proposed  [15] that SHBG can reduce ER  activity 
through ERK inhibition. It is actually known that ER  transcrip-
tional activity is increased by ERK-mediated phosphorylation 
 [41] and so SHBG-mediated ERK inhibition can downregulate 
ER  activity. 
 In conclusion, our study underlines the ability of SHBG to modu-
late estradiol-controlled gene expression in breast cancer cells; 
in particular, SHBG is effective on few selected genes which are 
involved in cell growth and apoptosis as well as on genes related 
to cell estrogen-dependence. The effect of SHBG in estrogen 
breast cancer cells, as previously suggested, is therefore strongly 
associated to cell growth and estrogen-sensitivity. 
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